Karpetsky T P, Humphrey R L, Levy C C
J Natl Cancer Inst. 1977 Apr;58(4):875-80. doi: 10.1093/jnci/58.4.875.
Serum RNase levels were measured in 34 patients with multiple myeloma and compared with 51 normal controls and 28 non-myeloma patients on chronic hemodialysis. Nineteen of the myeloma patinets with creatinine clearance (CCr) greater than 50 ml/minute had mean serum RNase levels that were statistically indistinguishable from those of the normal controls. The 15 myeloma patinets with CCr less than 50 ml/minute had mean RNase levels much higher than normal controls or myeloma patients with normal renal function. Patients without myeloma but on hemodialysis for chronic renal failure of varied etiologies had markedly elevated serum RNase levels. A strong correlation between RNase levels and renal insufficiency, as measured by CCr, has thus been demonstrated. In addition, case histories of 5 representative myeloma patients were analyzed in greater detail; they illustrated the rise and fall of RNase levels as a function of the status of their renal insufficiency, regardless of the extent of the underlying myeloma. We concluded that the serum RNase level was an indicator of renal function, and was not a biomarker either for the presence or extent of the plasma cell tumor.
对34例多发性骨髓瘤患者的血清核糖核酸酶（RNase）水平进行了测定，并与51名正常对照者以及28例接受慢性血液透析的非骨髓瘤患者进行了比较。19例肌酐清除率（CCr）大于50 ml/分钟的骨髓瘤患者，其血清RNase平均水平在统计学上与正常对照者无显著差异。15例CCr小于50 ml/分钟的骨髓瘤患者，其RNase平均水平远高于正常对照者或肾功能正常的骨髓瘤患者。因各种病因导致慢性肾衰竭而接受血液透析的非骨髓瘤患者，其血清RNase水平显著升高。由此证明，RNase水平与通过CCr测定的肾功能不全之间存在密切相关性。此外，对5例具有代表性的骨髓瘤患者的病例史进行了更详细的分析；这些病例表明，无论潜在骨髓瘤的程度如何，RNase水平会随着肾功能不全状况的变化而升降。我们得出结论，血清RNase水平是肾功能的一个指标，而不是浆细胞瘤存在或程度的生物标志物。
